Need For A Vaccines Unit In India Pushes GSK Closer To Align With India's Biological E; Is A Buyout Imminent ?
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - GlaxoSmithKline Plc.'s vaccines arm, the Belgium-headquartered GSK Biologicals S.A. is believed to be on course to acquire Hyderabad, India-based vaccines manufacturer Biological E. Ltd., a report in The Economic Times said last week. If the deal comes to fruition, GSK would fulfil its long desire to buy an Indian asset that could be leveraged for its expanding network in the high potential emerging markets